Instrument Inactif

Autres langues Proteostasis Therapeutics, Inc.

Actions

PTI

US74373B1098

Autres langues

23/12/20	Proteostasis Therapeutics, Inc.(NasdaqGM:PTI) dropped from NASDAQ Composite Index
22/12/20	Proteostasis Therapeutics, Inc. : Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio
22/12/20	Yumanity Therapeutics Inc. completed the acquisition of Proteostasis Therapeutics, Inc. in a reverse merger transaction.
16/12/20	PROTEOSTASIS THERAPEUTICS, INC. : Other Events (form 8-K)
15/12/20	PROTEOSTASIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
09/12/20	PROTEOSTASIS THERAPEUTICS, INC. : Other Events (form 8-K)
04/12/20	PROTEOSTASIS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
16/11/20	Proteostasis: 3Q Earnings Snapshot
16/11/20	Proteostasis: 3Q Earnings Snapshot
16/11/20	Proteostasis Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
16/11/20	Proteostasis Therapeutics : Reports Third Quarter 2020 Financial Results
16/11/20	PROTEOSTASIS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
06/11/20	PROTEOSTASIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
22/09/20	WeissLaw LLP : Reminds BYFC, OTEL and PTI Shareholders About Its Ongoing Investigations
17/09/20	PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events (form 8-K)
27/08/20	PROTEOSTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Proteostasis Therapeutics, Inc. - PTI
24/08/20	Proteostasis Therapeutics, Inc. Announces Resignation of Sheila Wilson as Chief Operating Officer
24/08/20	PROTEOSTASIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
24/08/20	Proteostasis Therapeutics : Biotech Startup Yumanity Sets Reverse Merger With Proteostasis
24/08/20	Proteostasis Therapeutics : Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
24/08/20	Yumanity Therapeutics Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Proteostasis Therapeutics, Inc. for approximately $150 million in a reverse merger transaction.
07/08/20	Proteostasis: 2Q Earnings Snapshot
06/08/20	Proteostasis Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
06/08/20	PROTEOSTASIS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
06/08/20	Proteostasis Therapeutics : Reports Second Quarter 2020 Financial Results